We are analyzing https://link.springer.com/article/10.1007/s10549-004-6454-7.

Title:
Prevention of metastases with a Mage-b DNA vaccine in a mouse breast tumor model: potential for breast cancer therapy | Breast Cancer Research and Treatment
Description:
Anti-tumor vaccines are a relatively non-toxic alternative to conventional chemotherapeutic strategies to control breast cancer. Immunization with tumor-associated antigens (TAAs) triggers anti-tumor cytotoxic T lymphocytes (CTL), which can limit tumor progression. Here we report on the development and effectiveness of a TAA-based DNA vaccine encoding Mage-b1/2, the mouse homologue of the human MAGE-B1/2. As model system, we used immune competent Balb/c mice with syngeneic non-metastatic (64pT) or metastatic (4TO7cg) breast tumors. First, the presence of Mage-btranscripts in the 64pT and 4TO7cg breast tumors and metastases was demonstrated by RT-PCR, Southern blotting, and DNA sequencing. A DNA-based vaccine was developed from transcripts of one of the 64pT tumors, encoding the complete Mage-b1/2 protein, and subsequently tested for its preventive efficacy in both breast tumor models. Mice were immunized two times intramuscularly with the vaccine (pcDNA3.1-Mage-b1/2-V5), the control vector (pcDNA3.1-V5), or saline. Two weeks after the last immunization, the syngeneic 4TO7cg or 64pT tumor cell lines were injected in a mammary fat pad. Mice were monitored during the next 4 weeks for tumor formation, latency and size, and subsequently sacrificed for analysis. While the Mage-b1/2 vaccine had only a minor effect on the latency and growth of primary tumors, a significant and reproducible reduction in the number of 4TO7cg metastases was observed (vaccine versus control vector, p=0.0329; vaccine versus saline, p=0.0128). The observed protective efficacy of the Mage-b DNA vaccine correlated with high levels of vaccine-induced IFNγ in spleen and lymph nodes upon re-stimulation in vitro. These results demonstrate the potential of TAA-based DNA vaccines in controlling metastatic disease in breast cancer patients.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Health & Fitness
Science
Education

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 7,626,932 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't figure out the monetization strategy.

While profit motivates many websites, others exist to inspire, entertain, or provide valuable resources. Websites have a variety of goals. And this might be one of them. Link.springer.com might be earning cash quietly, but we haven't detected the monetization method.

Keywords {🔍}

article, google, scholar, cancer, cas, pubmed, breast, vaccine, dna, tumor, vaccines, metastatic, mouse, mageb, model, patients, access, melanoma, metastases, gravekamp, human, mice, genes, privacy, cookies, content, research, search, sypniewska, immunization, tocg, tumors, boon, mage, nature, publish, treatment, potential, hoflack, tarango, immune, cell, open, cells, exp, immunol, immunology, res, miller, analysis,

Topics {✒️}

evdemon-hogan jr conejo-garcia babinet sy hwang month download article/chapter taa-based dna vaccines complete mage-b1/2 protein therapeutic cancer vaccines tailoring cancer vaccines triggers anti-tumor cytotoxic full article pdf melanoma peptide vaccines breast cancer therapy related subjects mayer jh peteres breast tumor models conaway fr miller control breast cancer ii breast cancer dna-based vaccine breast cancer patients mammary fat pad dna vaccines privacy choices/manage cookies mceachern fr miller article sypniewska mage-b1/2 vaccine mage-3 protein combined mage-expressing cancers miller dj lipman human mage-b1/2 dna vaccine correlated 4to7cg breast tumors elispot assay cancer article log nonmetastatic breast tumors observed protective efficacy melanocyte-specific antigen peptide-specific ctls vaccine-induced ifnγ chattergoon ml bagarazzi mouse genes homologous immune competent balb/ vaccine targeting top2a article cite metastatic cancer patients 1-mage-b1/2-v5 breast cancer mouse peritoneal macrophages overcome tumor escape check access instant access

Questions {❓}

H Scarth J Cantin M Levine (2002) Clinical practice guidelines for the care and treatment of breast cancer: Mastectomy or lumpectomy?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Prevention of metastases with a Mage-b DNA vaccine in a mouse breast tumor model: potential for breast cancer therapy
         description:Anti-tumor vaccines are a relatively non-toxic alternative to conventional chemotherapeutic strategies to control breast cancer. Immunization with tumor-associated antigens (TAAs) triggers anti-tumor cytotoxic T lymphocytes (CTL), which can limit tumor progression. Here we report on the development and effectiveness of a TAA-based DNA vaccine encoding Mage-b1/2, the mouse homologue of the human MAGE-B1/2. As model system, we used immune competent Balb/c mice with syngeneic non-metastatic (64pT) or metastatic (4TO7cg) breast tumors. First, the presence of Mage-btranscripts in the 64pT and 4TO7cg breast tumors and metastases was demonstrated by RT-PCR, Southern blotting, and DNA sequencing. A DNA-based vaccine was developed from transcripts of one of the 64pT tumors, encoding the complete Mage-b1/2 protein, and subsequently tested for its preventive efficacy in both breast tumor models. Mice were immunized two times intramuscularly with the vaccine (pcDNA3.1-Mage-b1/2-V5), the control vector (pcDNA3.1-V5), or saline. Two weeks after the last immunization, the syngeneic 4TO7cg or 64pT tumor cell lines were injected in a mammary fat pad. Mice were monitored during the next 4 weeks for tumor formation, latency and size, and subsequently sacrificed for analysis. While the Mage-b1/2 vaccine had only a minor effect on the latency and growth of primary tumors, a significant and reproducible reduction in the number of 4TO7cg metastases was observed (vaccine versus control vector, p=0.0329; vaccine versus saline, p=0.0128). The observed protective efficacy of the Mage-b DNA vaccine correlated with high levels of vaccine-induced IFNγ in spleen and lymph nodes upon re-stimulation in vitro. These results demonstrate the potential of TAA-based DNA vaccines in controlling metastatic disease in breast cancer patients.
         datePublished:
         dateModified:
         pageStart:19
         pageEnd:28
         sameAs:https://doi.org/10.1007/s10549-004-6454-7
         keywords:
            breast tumor model
            Mage-b DNA vaccine
            metastases
            4TO7cg model
            64pT model
            Oncology
         image:
         isPartOf:
            name:Breast Cancer Research and Treatment
            issn:
               1573-7217
               0167-6806
            volumeNumber:91
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Kluwer Academic Publishers
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Roza K. Sypniewska
               affiliation:
                     name:University of Texas Health Science Center
                     address:
                        name:Department of Cellular and Structural Biology, University of Texas Health Science Center, San Antonio, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Lieve Hoflack
               affiliation:
                     name:University of Texas Health Science Center
                     address:
                        name:Department of Cellular and Structural Biology, University of Texas Health Science Center, San Antonio, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Melissa Tarango
               affiliation:
                     name:University of Texas Health Science Center
                     address:
                        name:Department of Cellular and Structural Biology, University of Texas Health Science Center, San Antonio, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Susan Gauntt
               affiliation:
                     name:University of Texas Health Science Center
                     address:
                        name:Department of Cellular and Structural Biology, University of Texas Health Science Center, San Antonio, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Belinda Z. Leal
               affiliation:
                     name:University of Texas Health Science Center
                     address:
                        name:Department of Cellular and Structural Biology, University of Texas Health Science Center, San Antonio, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Robert L. Reddick
               affiliation:
                     name:University of Texas Health Science Center
                     address:
                        name:Department of Pathology, University of Texas Health Science Center, San Antonio, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Claudia Gravekamp
               affiliation:
                     name:University of Texas Health Science Center
                     address:
                        name:Department of Cellular and Structural Biology, University of Texas Health Science Center, San Antonio, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Prevention of metastases with a Mage-b DNA vaccine in a mouse breast tumor model: potential for breast cancer therapy
      description:Anti-tumor vaccines are a relatively non-toxic alternative to conventional chemotherapeutic strategies to control breast cancer. Immunization with tumor-associated antigens (TAAs) triggers anti-tumor cytotoxic T lymphocytes (CTL), which can limit tumor progression. Here we report on the development and effectiveness of a TAA-based DNA vaccine encoding Mage-b1/2, the mouse homologue of the human MAGE-B1/2. As model system, we used immune competent Balb/c mice with syngeneic non-metastatic (64pT) or metastatic (4TO7cg) breast tumors. First, the presence of Mage-btranscripts in the 64pT and 4TO7cg breast tumors and metastases was demonstrated by RT-PCR, Southern blotting, and DNA sequencing. A DNA-based vaccine was developed from transcripts of one of the 64pT tumors, encoding the complete Mage-b1/2 protein, and subsequently tested for its preventive efficacy in both breast tumor models. Mice were immunized two times intramuscularly with the vaccine (pcDNA3.1-Mage-b1/2-V5), the control vector (pcDNA3.1-V5), or saline. Two weeks after the last immunization, the syngeneic 4TO7cg or 64pT tumor cell lines were injected in a mammary fat pad. Mice were monitored during the next 4 weeks for tumor formation, latency and size, and subsequently sacrificed for analysis. While the Mage-b1/2 vaccine had only a minor effect on the latency and growth of primary tumors, a significant and reproducible reduction in the number of 4TO7cg metastases was observed (vaccine versus control vector, p=0.0329; vaccine versus saline, p=0.0128). The observed protective efficacy of the Mage-b DNA vaccine correlated with high levels of vaccine-induced IFNγ in spleen and lymph nodes upon re-stimulation in vitro. These results demonstrate the potential of TAA-based DNA vaccines in controlling metastatic disease in breast cancer patients.
      datePublished:
      dateModified:
      pageStart:19
      pageEnd:28
      sameAs:https://doi.org/10.1007/s10549-004-6454-7
      keywords:
         breast tumor model
         Mage-b DNA vaccine
         metastases
         4TO7cg model
         64pT model
         Oncology
      image:
      isPartOf:
         name:Breast Cancer Research and Treatment
         issn:
            1573-7217
            0167-6806
         volumeNumber:91
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Kluwer Academic Publishers
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Roza K. Sypniewska
            affiliation:
                  name:University of Texas Health Science Center
                  address:
                     name:Department of Cellular and Structural Biology, University of Texas Health Science Center, San Antonio, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Lieve Hoflack
            affiliation:
                  name:University of Texas Health Science Center
                  address:
                     name:Department of Cellular and Structural Biology, University of Texas Health Science Center, San Antonio, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Melissa Tarango
            affiliation:
                  name:University of Texas Health Science Center
                  address:
                     name:Department of Cellular and Structural Biology, University of Texas Health Science Center, San Antonio, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Susan Gauntt
            affiliation:
                  name:University of Texas Health Science Center
                  address:
                     name:Department of Cellular and Structural Biology, University of Texas Health Science Center, San Antonio, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Belinda Z. Leal
            affiliation:
                  name:University of Texas Health Science Center
                  address:
                     name:Department of Cellular and Structural Biology, University of Texas Health Science Center, San Antonio, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Robert L. Reddick
            affiliation:
                  name:University of Texas Health Science Center
                  address:
                     name:Department of Pathology, University of Texas Health Science Center, San Antonio, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Claudia Gravekamp
            affiliation:
                  name:University of Texas Health Science Center
                  address:
                     name:Department of Cellular and Structural Biology, University of Texas Health Science Center, San Antonio, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Breast Cancer Research and Treatment
      issn:
         1573-7217
         0167-6806
      volumeNumber:91
Organization:
      name:Kluwer Academic Publishers
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of Texas Health Science Center
      address:
         name:Department of Cellular and Structural Biology, University of Texas Health Science Center, San Antonio, USA
         type:PostalAddress
      name:University of Texas Health Science Center
      address:
         name:Department of Cellular and Structural Biology, University of Texas Health Science Center, San Antonio, USA
         type:PostalAddress
      name:University of Texas Health Science Center
      address:
         name:Department of Cellular and Structural Biology, University of Texas Health Science Center, San Antonio, USA
         type:PostalAddress
      name:University of Texas Health Science Center
      address:
         name:Department of Cellular and Structural Biology, University of Texas Health Science Center, San Antonio, USA
         type:PostalAddress
      name:University of Texas Health Science Center
      address:
         name:Department of Cellular and Structural Biology, University of Texas Health Science Center, San Antonio, USA
         type:PostalAddress
      name:University of Texas Health Science Center
      address:
         name:Department of Pathology, University of Texas Health Science Center, San Antonio, USA
         type:PostalAddress
      name:University of Texas Health Science Center
      address:
         name:Department of Cellular and Structural Biology, University of Texas Health Science Center, San Antonio, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Roza K. Sypniewska
      affiliation:
            name:University of Texas Health Science Center
            address:
               name:Department of Cellular and Structural Biology, University of Texas Health Science Center, San Antonio, USA
               type:PostalAddress
            type:Organization
      name:Lieve Hoflack
      affiliation:
            name:University of Texas Health Science Center
            address:
               name:Department of Cellular and Structural Biology, University of Texas Health Science Center, San Antonio, USA
               type:PostalAddress
            type:Organization
      name:Melissa Tarango
      affiliation:
            name:University of Texas Health Science Center
            address:
               name:Department of Cellular and Structural Biology, University of Texas Health Science Center, San Antonio, USA
               type:PostalAddress
            type:Organization
      name:Susan Gauntt
      affiliation:
            name:University of Texas Health Science Center
            address:
               name:Department of Cellular and Structural Biology, University of Texas Health Science Center, San Antonio, USA
               type:PostalAddress
            type:Organization
      name:Belinda Z. Leal
      affiliation:
            name:University of Texas Health Science Center
            address:
               name:Department of Cellular and Structural Biology, University of Texas Health Science Center, San Antonio, USA
               type:PostalAddress
            type:Organization
      name:Robert L. Reddick
      affiliation:
            name:University of Texas Health Science Center
            address:
               name:Department of Pathology, University of Texas Health Science Center, San Antonio, USA
               type:PostalAddress
            type:Organization
      name:Claudia Gravekamp
      affiliation:
            name:University of Texas Health Science Center
            address:
               name:Department of Cellular and Structural Biology, University of Texas Health Science Center, San Antonio, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Cellular and Structural Biology, University of Texas Health Science Center, San Antonio, USA
      name:Department of Cellular and Structural Biology, University of Texas Health Science Center, San Antonio, USA
      name:Department of Cellular and Structural Biology, University of Texas Health Science Center, San Antonio, USA
      name:Department of Cellular and Structural Biology, University of Texas Health Science Center, San Antonio, USA
      name:Department of Cellular and Structural Biology, University of Texas Health Science Center, San Antonio, USA
      name:Department of Pathology, University of Texas Health Science Center, San Antonio, USA
      name:Department of Cellular and Structural Biology, University of Texas Health Science Center, San Antonio, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(108)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

3.71s.

LINK . SPRINGER . COM {}